Physician profile
Ronald Alan Mudry
NPI 1710081864
$848.77
in general payments reported to CMS, 2019-2025
13 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $26.56 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $252.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $336.15 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Insmed, INC. | $132.84 | 2019 | |
| Sunovion Pharmaceuticals INC. | $83.69 | 2019 | |
| Glaxosmithkline, LLC. | $74.92 | 2019-2025 | Nucala |
| Resmed Corp | $61.06 | 2019-2020 | |
| Viatris Specialty LLC | $46.46 | 2025 | Yupelri |
| Verona Pharma, INC. | $38.40 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $20.56 | 2019 | |
| Csl Behring | $16.82 | 2019 | |
| Shire North American Group INC | $14.47 | 2019 | |
| Mylan Specialty L.P. | $12.25 | 2019 | |
| Electromed, INC. | $11.15 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Mudry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.